NARDO, ANTONELLA
 Distribuzione geografica
Continente #
AS - Asia 206
NA - Nord America 192
EU - Europa 86
SA - Sud America 36
AF - Africa 33
Totale 553
Nazione #
US - Stati Uniti d'America 186
CN - Cina 85
SG - Singapore 76
IT - Italia 58
BR - Brasile 28
CI - Costa d'Avorio 27
KR - Corea 24
IN - India 9
GB - Regno Unito 6
VN - Vietnam 6
FI - Finlandia 5
IE - Irlanda 4
PL - Polonia 4
SE - Svezia 4
AR - Argentina 3
BJ - Benin 3
CA - Canada 3
MX - Messico 3
BD - Bangladesh 2
EC - Ecuador 2
BE - Belgio 1
CL - Cile 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DE - Germania 1
FR - Francia 1
IQ - Iraq 1
JP - Giappone 1
NL - Olanda 1
OM - Oman 1
PK - Pakistan 1
SC - Seychelles 1
SN - Senegal 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 553
Città #
Dallas 72
Hefei 52
Singapore 43
Santa Clara 36
Abidjan 27
Seoul 24
Chicago 15
Ashburn 12
Los Angeles 9
Civitanova Marche 8
Milan 7
Beijing 6
Boardman 5
New York 5
Catania 4
Dublin 4
Stockholm 4
Chennai 3
Cotonou 3
Denver 3
Manchester 3
Mexico City 3
Palermo 3
Rome 3
Tremestieri Etneo 3
Warsaw 3
Buffalo 2
Campinas 2
Florence 2
Guayaquil 2
Helsinki 2
Lappeenranta 2
London 2
Louisville 2
Mumbai 2
São Paulo 2
Aragona 1
Baghdad 1
Barueri 1
Belpasso 1
Birigui 1
Bogotá 1
Brasília 1
Bronte 1
Brooklyn 1
Brussels 1
Buenos Aires 1
Bắc Ninh 1
Campos do Jordão 1
Can Tho 1
Cantanhede 1
Cao Lanh 1
Caucaia 1
Chongqing 1
Curitiba 1
Dakar 1
Dalian 1
Extrema 1
Fazenda Rio Grande 1
Fort St. James 1
Franca 1
Genoa 1
Hanoi 1
Ho Chi Minh City 1
Itaberaba 1
Itaquaquecetuba 1
Johannesburg 1
La Plata 1
Lahore 1
Langfang 1
Linyi 1
Mariana 1
Messina 1
Montreal 1
Munich 1
Naples 1
New Delhi 1
Newmarket 1
Nova Iguaçu 1
Olomouc 1
Orem 1
Osasco 1
Paris 1
Passa e Fica 1
Phoenix 1
Pirenópolis 1
Poplar 1
Pune 1
Rancagua 1
Registro 1
Rio de Janeiro 1
San Francisco 1
Santa Maria 1
Santos 1
Satna 1
Seeb 1
Sumaré 1
Sítio Novo do Tocantins 1
Teixeirópolis 1
Tokyo 1
Totale 444
Nome #
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 85
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 84
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 81
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 80
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 69
Emergencies in Hematology: Why, When and How I Treat? 68
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 49
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 46
Totale 562
Categoria #
all - tutte 2.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.027


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202317 0 0 0 0 0 0 4 2 4 0 7 0
2023/202456 0 4 2 9 0 14 10 1 0 3 12 1
2024/2025183 1 24 5 14 25 26 8 5 12 15 25 23
2025/2026306 41 82 80 48 55 0 0 0 0 0 0 0
Totale 562